ホーム / コンテンツ / オンデマンド・ウェビナー / Itraconazole – Comparison of PBPK models for evaluation of clinical PK exposure and DDIs
Itraconazole – Comparison of PBPK models for evaluation of clinical PK exposure and DDIs
オンデマンド・ウェビナー

Since the withdrawal of Ketoconazole due to concerns over hepatotoxicity, Itraconazole is commonly used in DDI studies as a strong selective inhibitor of CYP3A4. A number of PBPK models are available for use in the Simcyp Simulator including, the First Order and ADAM library files and the recently published models by the IQ Consortium. In this webinar, Dr. Peter Kilford, Certara UK Ltd, Simcyp Division discussed the PBPK models that are available and evaluated their predictive performance against a number of clinical PK and DDI studies.

トップに戻る
Powered by Translations.com GlobalLink OneLink Software